人表皮生长因子受体2抑制剂对乳腺癌患者的心脏毒性及防治策略  

Prevention and Treatment Strategies of Human Epidermal Growth Factor Receptor 2 Inhibitors Associated Cardiotoxicity in Breast Cancer Patients

作　　者：史云静 邱泽平 金玮[1] SHI Yun-jing;QIU Ze-ping;JIN Wei(Department of Cardiology,Ruijin Hospial,Shanghai Jiao Tong University Schoo of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院心脏内科,上海市200025

出　　处：《中国分子心脏病学杂志》2021年第5期4258-4263,共6页Molecular Cardiology of China

基　　金：国家自然科学基金(81970337)。

摘　　要：20%~30%的乳腺癌患者人表皮生长因子受体2(HER2)呈过表达,HER2靶向药物在临床的广泛应用显著改善了HER2阳性乳腺癌患者的预后。但大量研究表明HER2抑制剂具有心脏毒性,认识并防治HER2抑制剂相关心脏毒性对提高乳腺癌患者的长期生存质量具有重要意义。本文从临床和基础两方面阐述HER2抑制剂对乳腺癌患者心脏毒性的临床研究、内在机制及治疗策略,并从机制上探索防治HER2抑制剂相关心脏毒性的潜在策略。Totally 20%-30%of breast cancer patients are overexpressed in human epidermal growth factor receptor 2(HER2),the widespread application of HER2 targeted agents has significantly improved the prognosis of HER2-positive breast cancer patients.However,multiple studies have demonstrated the cardiotoxicity of HER2 inhibitors.The recognition and prevention of HER2 inhibitor-related cardiotoxicity is of great significance for improving breast cancer patients’quality of life in the long term.Therefore,we will briefly illustrate the clinical research,underlying mechanism and treatment strategies of HER2 inhibitor-related cardiotoxicity in breast cancer patients from both clinical and basic studying areas,and explore potential prevention and treatment strategies based on the mechanism.

关 键 词：乳腺癌 人表皮生长因子受体2抑制剂 心脏毒性 防治 

分 类 号：R737.9[医药卫生—肿瘤]